Tetracycline and Toxicity Induced
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Role of Nanobiosensors in Therapeutic Drug Monitoring
Journal of Personalized Medicine Review Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring Vivian Garzón 1, Rosa-Helena Bustos 2 and Daniel G. Pinacho 2,* 1 PhD Biosciences Program, Universidad de La Sabana, Chía 140013, Colombia; [email protected] 2 Therapeutical Evidence Group, Clinical Pharmacology, Universidad de La Sabana, Chía 140013, Colombia; [email protected] * Correspondence: [email protected]; Tel.: +57-1-8615555 (ext. 23309) Received: 21 August 2020; Accepted: 7 September 2020; Published: 25 September 2020 Abstract: Due to the high bacterial resistance to antibiotics (AB), it has become necessary to adjust the dose aimed at personalized medicine by means of therapeutic drug monitoring (TDM). TDM is a fundamental tool for measuring the concentration of drugs that have a limited or highly toxic dose in different body fluids, such as blood, plasma, serum, and urine, among others. Using different techniques that allow for the pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the drug, TDM can reduce the risks inherent in treatment. Among these techniques, nanotechnology focused on biosensors, which are relevant due to their versatility, sensitivity, specificity, and low cost. They provide results in real time, using an element for biological recognition coupled to a signal transducer. This review describes recent advances in the quantification of AB using biosensors with a focus on TDM as a fundamental aspect of personalized medicine. Keywords: biosensors; therapeutic drug monitoring (TDM), antibiotic; personalized medicine 1. Introduction The discovery of antibiotics (AB) ushered in a new era of progress in controlling bacterial infections in human health, agriculture, and livestock [1] However, the use of AB has been challenged due to the appearance of multi-resistant bacteria (MDR), which have increased significantly in recent years due to AB mismanagement and have become a global public health problem [2]. -
Antibiotic and Antibiotic Resistance
ANTIBIOTIC AND ANTIBIOTIC RESISTANCE Helle Ericsson Unnerstad Veterinarian, Associate Professor Department of Animal Health and Antimicrobial Strategies National Veterinary Institute, Uppsala, Sweden ITP, SVA, 28 September, 2018 Antibiotics or antimicrobials? • Old definition: Antibiotics are naturally produced by microorganisms. • Perhaps more useful definitions today: Antimicrobials are compounds with direct action on microorganisms. They are used for treatment or prevention of infections. Antimicrobials are inclusive of anti-bacterials, anti-virals, anti-fungals and anti-protozoals. Antibiotics are synonymous with anti-bacterials. • “Antibiotic resistance” more familiar for the public than “antimicrobial resistance” according to WHO survey. • In many contexts antibiotic resistance and antimicrobial resistance are used synonymously. Antibiotics – toxins for bacteria Antibiotic Antibiotic activity • Bactericidal activity – kill bacteria • Bacteriostatic activity – inhibit or delay bacterial growth Mechanisms of action for antibiotics Inhibition of Inhibition of cell wall synthesis protein synthesis • Aminoglycosides • Beta lactams • Tetracyclines • Cephalosporins • Macrolides • Glycopeptides • Lincosamides • Chloramphenicol • Fusidic acid • Pleuromutilins Inhibition of Inhibition of folic acid synthesis DNA/RNA synthesis • Sulphonamides • Quinolones • Trimethoprim • Coumarins • Rifamycins Spectra of activity • Broad-spectrum antibiotics Ex. tetracyclines, fluoroquinolones, 3:d and 4:th gen cephalosporins, carbapenems (G+, G-, aerobes, -
Oxytetracycline for Recurrent Blepharitis and Br J Ophthalmol: First Published As 10.1136/Bjo.79.1.42 on 1 January 1995
42 British rournal of Ophthalmology 1995; 79: 42-45 Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and Br J Ophthalmol: first published as 10.1136/bjo.79.1.42 on 1 January 1995. Downloaded from rosacea D V Seal, P Wright, L Ficker, K Hagan, M Troski, P Menday Abstract topical and systemic anti-staphylococcal A prospective, randomised, double blind, antibiotics in addition to anti-inflammatory partial crossover, placebo controlled trial therapy. has been conducted to compare the Fusidic acid has been in clinical use since performance of topical fusidic acid gel 1962 and is particularly effective against (Fucithalmic) and oral oxytetracycline as staphylococci. It has a steroid structure but no treatment for symptomatic chronic glucocorticoid activity. A new gel preparation blepharitis. Treatment success was containing 1% microcrystalline fusidic acid judged both by a reduction in symptoms (Fucithalmic) has recently been shown to be and clinical examination before and after effective for treating acute bacterial conjunc- therapy. Seventy five per cent of patients tivitis and for reducing the staphylococcal lid with blepharitis and associated rosacea flora before surgery.5-8 were symptomatically improved by Oxytetracycline has been selected for the fusidic acid gel and 500/0 by oxytetra- treatment of patients with chronic blepharitis cycline, but fewer (35%/o) appeared to as it has both anti-inflammatory and anti- benefit from the combination. Patients staphylococcal properties.9 10 It has been with chronic blepharitis of other aetiolo- demonstrated to be effective in a controlled gies did not respond to fusidic acid gel but trial in ocular rosacea for comeal infiltrates and 25% did benefit from oxytetracycline and conjunctival hyperaemiaII and in non-ocular 300/0 from the combination. -
Environmental Risk Assessment of Antibiotics: Investigations Into Cyanobacteria Interspecies Sensitivities and Establishing Appropriate Protection Limits
Environmental Risk Assessment of Antibiotics: Investigations into Cyanobacteria Interspecies Sensitivities and Establishing Appropriate Protection Limits Submitted by Gareth Curtis Le Page to the University of Exeter as a thesis for the degree of Doctor of Philosophy in Biological Sciences In December 2018 This thesis is available for Library use on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement I certify that all material in this thesis which is not my own work has been identified and that no material has previously been submitted and approved for the award of a degree by this or any other University. Signature: …………………………………………………………...(Gareth Le Page) 1 Abstract Antibiotics have been described as a ‘wonder drug’ that have transformed medicine since their discovery at the beginning of the 20th century and are used globally in safeguarding human and animal health. Environmental risk assessment (ERA) aims to ensure their environmental safety by setting protection limits that seek to prevent adverse effects upon populations and ecosystem function. In the case of antibiotics however, there is concern that ERA may not be fully protective of bacterial populations. This thesis examines the ERA of antibiotics and highlights that protection limits may in some cases be under-protective or over-protective for bacteria populations (including cyanobacteria), depending on the antibiotic mode of action and the species on which the protection limit is based. The first section of the thesis contains a systematic review including a meta-analysis of all publically available aquatic ecotoxicity data. The results illustrate that generally bacteria are the most sensitive taxa to antibiotics compared with eukaryotes but that interspecies variability in sensitivity among bacteria can range by up to five orders of magnitude. -
(OTC) Antibiotics in the European Union and Norway, 2012
Perspective Analysis of licensed over-the-counter (OTC) antibiotics in the European Union and Norway, 2012 L Both 1 , R Botgros 2 , M Cavaleri 2 1. Public Health England (PHE), London, United Kingdom 2. Anti-infectives and Vaccines Office, European Medicines Agency (EMA), London, United Kingdom Correspondence: Marco Cavaleri ([email protected]) Citation style for this article: Both L, Botgros R, Cavaleri M. Analysis of licensed over-the-counter (OTC) antibiotics in the European Union and Norway, 2012. Euro Surveill. 2015;20(34):pii=30002. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2015.20.34.30002 Article submitted on 16 September 2014 / accepted on 09 February 2015 / published on 27 August 2015 Antimicrobial resistance is recognised as a growing throughout the EU; however, there are still consider- problem that seriously threatens public health and able differences in Europe due to the different health- requires prompt action. Concerns have therefore been care structures and policies (including the extent of raised about the potential harmful effects of making pharmacist supervision for OTC medicines), reimburse- antibiotics available without prescription. Because of ment policies, and cultural differences of each Member the very serious concerns regarding further spread of State. Therefore, the availability of OTC medicines var- resistance, the over-the-counter (OTC) availability of ies in the EU and products sold as POM in certain coun- antibiotics was analysed here. Topical and systemic tries can be obtained as OTC medicines in others. OTC antibiotics and their indications were determined across 26 European Union (EU) countries and Norway As risk minimisation is an important criterion for some by means of a European survey. -
Farrukh Javaid Malik
I Farrukh Javaid Malik THESIS PRESENTED TO OBTAIN THE GRADE OF DOCTOR OF THE UNIVERSITY OF BORDEAUX Doctoral School, SP2: Society, Politic, Public Health Specialization Pharmacoepidemiology and Pharmacovigilance By Farrukh Javaid Malik “Analysis of the medicines panorama in Pakistan – The case of antimicrobials: market offer width and consumption.” Under the direction of Prof. Dr. Albert FIGUERAS Defense Date: 28th November 2019 Members of Jury M. Francesco SALVO, Maître de conférences des universités – praticien hospitalier, President Université de Bordeaux M. Albert FIGUERAS, Professeur des universités – praticien hospitalier, Director Université Autonome de Barcelone Mme Antonia AGUSTI, Professeure, Vall dʹHebron University Hospital Referee Mme Montserrat BOSCH, Praticienne hospitalière, Vall dʹHebron University Hospital Referee II Abstract A country’s medicines market is an indicator of its healthcare system, the epidemiological profile, and the prevalent practices therein. It is not only the first logical step to study the characteristics of medicines authorized for marketing, but also a requisite to set up a pharmacovigilance system, thus promoting rational drug utilization. The three medicines market studies presented in the present document were conducted in Pakistan with the aim of describing the characteristics of the pharmaceutical products available in the country as well as their consumption at a national level, with a special focus on antimicrobials. The most important cause of antimicrobial resistance is the inappropriate consumption of antimicrobials. The results of the researches conducted in Pakistan showed some market deficiencies which could be addressed as part of the national antimicrobial stewardship programmes. III Résumé Le marché du médicament d’un pays est un indicateur de son système de santé, de son profil épidémiologique et des pratiques [de prescription] qui y règnent. -
Withdrawal Times of Oxytetracycline and Tylosin in Eggs of Laying Hens After Oral Administration
1017 Journal of Food Protection, Vol. 77, No. 6, 2014, Pages 1017–1021 doi:10.4315/0362-028X.JFP-13-440 Copyright G, International Association for Food Protection Research Note Withdrawal Times of Oxytetracycline and Tylosin in Eggs of Laying Hens after Oral Administration RUBE´ N MUN˜ OZ,1 JAVIERA CORNEJO,2 ALDO MADDALENO,1 CAROLINA ARAYA-JORDA´ N,1 DANIELA IRAGU¨ EN,1 NICOLA´ S PIZARRO,1 AND BETTY SAN MARTI´N1* 1 2 Laboratory of Veterinary Pharmacology and Department of Animal Preventive Medicine, Faculty of Veterinary and Animal Sciences, Downloaded from http://meridian.allenpress.com/jfp/article-pdf/77/6/1017/1687041/0362-028x_jfp-13-440.pdf by guest on 30 September 2021 Universidad de Chile, Avenida Santa Rosa 11735, La Pintana, Santiago, Chile MS 13-440: Received 3 October 2013/Accepted 3 January 2014 ABSTRACT Antimicrobials administered to laying hens may be distributed into egg white or yolk, indicating the importance of evaluating withdrawal times (WDTs) of the pharmaceutical formulations. In the present study, oxytetracycline and tylosin’s WDTs were estimated. The concentration and depletion of these molecules in eggs were linked to their pharmacokinetic and physicochemical properties. Twenty-seven Leghorn hens were used: 12 treated with oxytetracycline, 12 treated with tylosin, and 3 remained as an untreated control group. After completion of therapies, eggs were collected daily and drug concentrations in egg white and yolk were assessed. The yolk was used as the target tissue to evaluate the WDT; the results were 9 and 3 days for oxytetracycline and tylosin, respectively. In particular, oxytetracycline has a good oral bioavailability, a moderate apparent volume of distribution, a molecular weight of 460 g/mol, and is lightly liposoluble. -
Structural Basis for Potent Inhibitory Activity of the Antibiotic Tigecycline During Protein Synthesis
Structural basis for potent inhibitory activity of the antibiotic tigecycline during protein synthesis Lasse Jennera,b,1, Agata L. Starostac,1, Daniel S. Terryd,e, Aleksandra Mikolajkac, Liudmila Filonavaa,b,f, Marat Yusupova,b, Scott C. Blanchardd, Daniel N. Wilsonc,g,2, and Gulnara Yusupovaa,b,2 aInstitut de Génétique et de Biologie Moléculaire et Cellulaire, Institut National de la Santé et de la Recherche Médicale U964, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 7104, 67404 Illkirch, France; bUniversité de Strasbourg, F-67084 Strasbourg, France; cGene Center and Department for Biochemistry, University of Munich, 81377 Munich, Germany; dDepartment of Physiology and Biophysics, Weill Medical College of Cornell University, New York, NY 10065; eTri-Institutional Training Program in Computational Biology and Medicine, New York, NY 10065; fMax Planck Institute for Biophysical Chemistry, 37077 Göttingen, Germany; and gCenter for Integrated Protein Science Munich, University of Munich, 81377 Munich, Germany Edited by Rachel Green, Johns Hopkins University, Baltimore, MD, and approved January 17, 2013 (received for review September 28, 2012) + Here we present an X-ray crystallography structure of the clinically C1054 via a coordinated Mg2 ion (Fig. 1 D and E), as reported relevant tigecycline antibiotic bound to the 70S ribosome. Our previously for tetracycline (2). In addition, ring A of tigecycline + structural and biochemical analysis indicate that the enhanced coordinates a second Mg2 ion to facilitate an indirect interaction potency of tigecycline results from a stacking interaction with with the phosphate-backbone of G966 in h31 (Fig. 1 C–E). We also nucleobase C1054 within the decoding site of the ribosome. -
Blepharitis Last Revised in October 2015
Menu Sign in (https://accounts.nice.org.uk/signin) Search... Blepharitis Last revised in October 2015 Changes Back to top Last revised in October 2015 October 2015 — reviewed. A literature search was conducted in October 2015 to identify evidence based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No changes to clinical recommendations have been made. Previous changes Back to top September 2012 — reviewed. A literature search was conducted in September 2012 to identify evidencebased guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. No changes to clinical recommendations have been made. April 2011 — minor update. Change to recommendation regarding need for additional contraception during or after a course of tetracycline additional contraception is no longer required when using antibiotics that are not enzyme inducers with combined hormonal methods for durations of 3 weeks or less [FSRH, 2011 (/blepharitis#!references/315093)]. Issued in June 2011. March 2011 — topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made. September 2010 — minor update. Hydromoor® (hypromellose 0.3% preservativefree single dose eye drops) have been included. Issued in September 2010. March 2010 — minor update. LubriTears® eye ointment has been discontinued. Prescription removed. Issued in March 2010. December 2007 to May 2008 — converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. The clinical scenario structure has been reviewed. -
Treatment with Sub-Inhibitory Kanamycin Induces Adaptive Resistance to Aminoglycoside Antibiotics Via the Acrd Multidrug Efflux Pump in Escherichia Coli K-12
Journal of Experimental Microbiology and Immunology (JEMI) Vol. 16: 11 – 16 Copyright © April 2012, M&I UBC Treatment with Sub-inhibitory Kanamycin Induces Adaptive Resistance to Aminoglycoside Antibiotics via the AcrD Multidrug Efflux Pump in Escherichia coli K-12 Kiran Sidhu, Martha Talbot, Kirstin Van Mil, and Meghan Verstraete Department of Microbiology & Immunology, University of British Columbia Research has shown that exposing Escherichia coli cells to sub-inhibitory concentrations of kanamycin induces adaptive resistance upon subsequent exposure to lethal levels of both structurally-similar and unrelated antibiotics. AcrD is an efflux pump that forms a complex with the outer membrane pore TolC and the periplasmic membrane fusion protein AcrA. Together, this complex works to export a variety of aminoglycosides and amphiphilic compounds from the cell. The involvement of AcrD in the observed adaptive resistance was assessed by comparing the induction of adaptive resistance upon exposure to kanamycin in wild- type and acrD-deficient Escherichia coli strains. Both strains were pretreated with sub- inhibitory concentrations of kanamycin and subsequently exposed to lethal concentrations of ampicillin, kanamycin, nalidixic acid, streptomycin, and tetracycline. Growth was monitored over 18 hours via optical density readings. Comparing the relative growth of the different treatments revealed that adaptive resistance was only induced in the wild-type strain towards kanamycin and streptomycin. This indicates that AcrD is necessary for the induced adaptive resistance and that it is specific to aminoglycosides. Additionally, molecular techniques were used to assess the level of expression of acrA, which was found to be upregulated in both the wild-type and acrD deletion strains following pretreatment with kanamycin. -
(ESVAC) Web-Based Sales and Animal Population
16 July 2019 EMA/210691/2015-Rev.2 Veterinary Medicines Division European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) Sales Data and Animal Population Data Collection Protocol (version 3) Superseded by a new version Superseded Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of content 1. Introduction ....................................................................................................................... 3 1.1. Terms of reference ........................................................................................................... 3 1.2. Approach ........................................................................................................................ 3 1.3. Target groups of the protocol and templates ......................................................................... 4 1.4. Organization of the ESVAC project ...................................................................................... 4 1.5. Web based delivery of data ................................................................................................ 5 2. ESVAC sales data ............................................................................................................... 5 2.1. -
Topical Antibiotics
Topical antibiotics Microbiological point of view [email protected] • Topical antibiotics • Efficacy • Antibiotic resistance – Propionibacteria/acne • Tetracyclines • macrolides – Staphylococci/impetigo • Fusidic acid • Mupirocin • Epilogue Topical antibiotics in dermatology • Bacitracin • Chloramphénicol • Clindamycin • Erythromycin • Fusidic acid • Gentamicin • Miconazol • Mupirocin • Neomycin • Polymyxin B • Sulfamides • Tétracyclines • Benzoyle peroxyde • Azelaic acid + “bactéries (filtrat polyvalent) + huile de foie de morue 125 mg + sulfanilamide 200 mg/1 g “ Topical antibiotics in ophtalmology / ORL • Bacitracine • Chloramphénicol • Fusidic acid • Gentamicin • Gramicidin* • Quinolones: o-,nor-, cipro-, lome- floxacin* • Neomycin • Polymyxin B • Rifamycin* • Sulfamides • Tétracyclines • Trimethoprim* • Tobramycin* • Tyrothricine* Topical antibiotics: efficacy • Impetigo: mupirocin & fusidic acid*: + ** • Acne: + ~ benzoyl peroxyde • Chronic suppurative otitis media*: + ** • Acute bacterial conjunctivitis*: + * (Cochrane review) ** better than antiseptics Topical antibiotics: resistance • Propionibacterium spp: resistance to erythromycin: – mutation in the genes encoding 23S ribosomal RNA (3 phenotypes) resistance to tetracycline: – Mutation of the gene encoding 16S ribosomal RNA Propionibacteria Distribution and differentiation of human commensal propionibacterium P. acnes P. avidum P. granulosum P. propionicum distribution Skin +++ +++ +++ - Eye + - - +++ Mouth ++ - + +++ Gut +++ - - - differentiation Esculin - + - - Catalase +